• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by CollPlant Biotechnologies Ltd

    6/9/25 7:08:40 AM ET
    $CLGN
    Industrial Specialties
    Health Care
    Get the next $CLGN alert in real time by email
    6-K 1 ea0245094-6k_collplant.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

    THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of June 2025

    Commission File Number 001-38370

     

    CollPlant Biotechnologies Ltd.

    (Exact name of registrant as specified in its charter)

     

    4 Oppenheimer St, Weizmann Science Park

    Rehovot 7670104, Israel

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒          Form 40-F ☐

     

     

     

     

     

     

    On June 9, 2025, CollPlant Biotechnologies Ltd. issued a press release entitled “CollPlant broadens its collaboration with STEMCELL Technologies”. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

     

    Attached hereto and incorporated by reference herein are the following exhibits:

     

    99.1   Press Release, dated June 9, 2025.

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      COLLPLANT BIOTECHNOLOGIES LTD.
           
    Date: June 9, 2025 By: /s/ Eran Rotem
        Name: Eran Rotem
        Title: Deputy CEO and Chief Financial Officer

     

    2

     

    Get the next $CLGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLGN

    DatePrice TargetRatingAnalyst
    2/17/2023$22.75Buy
    Alliance Global Partners
    More analyst ratings